Precision Medicine Day Two

 

Precision 2018 Day 2

08:00 Registration opens

Opening keynotes: Precision medicine stories

08:55

Chair's opening remarks

09:00

Precision medicine stories from inside

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Paul Peter Tak
09:25

Towards prevention of autoimmune disease: the example of rheumatoid arthritis

  • Predictors for rheumatoid arthritis (RA) development will be presented
  • PRAIRI study is the first evaluating the effects of a biopharmaceutical in subjects at risk of developing RA
  • A single infusion of 1000 mg rituximab delays the development of arthritis up to 12 months
Kari Stefansson
09:50

From discovery genetics to precision medicine

10:15

Reserved for supporting partner

Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details

10:40 Networking Break

round tables
11:40

Roundtable discussion session

This roundtable session will run as two, 30 minute rotations, enabling you to join 2 roundtables of your choice
Table 1: Health economics meets real world data
Table 2: Ethics to consider when discussing precision medicine
Table 4: Cost and benefits of precision medicine
Alastair Kent OBE

Alastair Kent OBE, Ambassador, Genetic Alliance U.K.

Table 5: Implementing precision medicine in healthcare systems
Table 6: Diagnostics – where precision medicine will take us
Table 7: Whole body screening – the future of healthcare
Table 8: Precision medicine for infectious disease
12:40

Speed Networking

A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings)
Panel discussion
13:00

13:00 Networking Lunch

Break out panel: Patient involvement in precision medicine
  • What are the benefits of involving the public in precision medicine
  • The patient experience with precision medicine and patient involvement
  • How clinicians can improve the patient experience
  • What are the barriers to involvement and how can they be overcome

Drug development

Precision Medicine - Oncology

Precision Medicine - Oncology

Chaired by TBC

Precision Medicine - Oncology
14:30

Mendelian genomics and precision medicine efforts at Yale

  • Biomarker discovery for Mendelian and Cancer Genomics
  • Precision Medicine initiative/efforts at Yale
  • Present PM cases of liver and brain cancer
  • Impact of new and upcoming technologies on PM
Drug Development
14:50

A precision medicine approach to tackling neurological diseases

Precision Medicine - Oncology
14:50

The Human Protein Atlas - implications for human biology and precision medicine

  • Knowledge of the spatial distribution of proteins is essential to understand human biology in health and disease
  • The Human Protein Atlas constitutes an open-access knowledge-based resource, focusing on an integrated omics approach for in situ detection of human proteins down to the single cell level
  • All human protein coding genes have been classified using a combination of genomics, transcriptomics, proteomics and antibody-based profiling, and used for studying global protein expression patterns
Drug Development
15:10

The evolution of Pharmacogenetics (PGx) as a tool to support drug development

  • What have we learned about PGx over the last 10 years
  • How best can we utilise this to support drug development going forward
  • The utility of clinical trials and PGx to support target validation
Precision Medicine - Oncology
15:10

Genomic medicine implementation

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Catrin Middleton, Senior Research and Clinical Patient Involvement Manager, Cancer Research UK
Drug Development
15:30

Implementing precision medicines: what are the challenges?

  • Sharing of case-studies/examples on challenges and solutions in precision medicine development through to integration in treatment pathways, including;
  • Biomarker discovery
  • Clinical trial design and delivery
  • Drug-diagnostic co-development
  • Precision Medicine launch and delivery to the patient
Precision Medicine - Oncology
15:30

Precision medicine in oncology: what is it exactly and where are we?

  • A better understanding of cancer biology has opened the door of precision medicine in oncology
  • The identification of specific molecular alterations in some tumour types has translated into major therapeutic achievements
  • High throughput technologies have allowed the elaboration of prognostic signatures that led to treatment de-intensification in breast cancer
  • However, it has not been demonstrated to date that the use of high throughput technologies to guide therapy improved patients’ outcomes
Vivienne Parry
15:50

15:50 Networking break

Breakout Panel: Inside the ethics committee – the ethics behind using precision medicine
  • Panel exploring the various ethical implications surrounding precision medicine
  • Big data and patient data usage
  • Best practice for ethical decisions

Precision Medicine - Rare Disease

Healthcare Track

Drug development

Healthcare Track

Chaired by TBC

Drug Development
16:30

Major public-private biomedical research partnership managed by the Foundation for the National Institute of Health

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Precision Medicine - Rare Disease
16:30

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

  • There is a need for new methods able to better discriminate between sensitive and resistant tumours to a given cancer treatment from the genomic profiles of these tumours
  • Combining multiple gene mutations via machine learning results in better discrimination than that provided by the best single-gene marker in about half of the 127 analysed drugs
  • Importantly, the proportion of sensitive cell lines that are correctly predicted as sensitive (recall) of the single-gene marker was lower than that of the multi-gene marker in 93% of the drugs
Healthcare Track
16:30

What does good care feel like? A patient's perspective

  • What do we mean by precision medicine? 
  • Expectations, fears and hope
  • Precision - in care, treatment and communication
Drug Development
16:50

Genomic scale drug design

  • First time in history we can have full genome binding affinity for molecules
  • This will shift the industry to a different design process, less risky, more precise
  • Opening of the single genome drug optimisation
Healthcare Track
16:50

Cancer susceptibility – screening and prevention using genomics

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Drug Development
17:10

Analytical tools to help with drug development

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Precision Medicine - Rare Disease
17:10

Need for patient registries for rare disease clinical trials and how to integrate them into the EMR

  • Hear how Sanford Research built a registry for batten disease and how they are expanding it and implementing it into electronic health records
  • What do these registries mean for clinical trials in the rare disease field?
  • How do approaches to registries and electronic health systems differ globally?
Healthcare Track
17:10

Actionable genes

  • The payer perspective of the genetic testing market
  • What our customers want
  • Actionable and teiring of genes
  • Commissioning of genetic tests
Drug Development
17:30

Academic built compounds (ABC) – with the move to drug discovery platforms are we forgetting our ABCs?

  • An overview of the Oncology drug development landscape - comparing approaches and exhibiting the successes from Academia
  • MicroQuin is offering a novel approach and first-in-class treatment to ALL Breast Cancers.  This will spotlight MicroQuin’s efforts and explain why this can’t be found using a platform approach
  • Examining the Oncology pipeline: The next generation drugs and why ABC is still unbeatable
Precision Medicine - Rare Disease
17:30

Induced pluripotent stem cells as a workhorse for human genetic studies

  • Learn how human iPS cells are transforming the study of disease alleles
  • What are the opportunities and challenges in using iPSCs as disease models?
  • Introduction to the Human Induced Pluripotent Stem Cells Initiative (HipSci)
Healthcare Track
17:30

Migrating Breast Health screening from imaging to metabolic detection via Wearable technology and Artificial Intelligence for the mass population

  • Hospital based breast cancer detection serves only a small percentage of the total population due to physician access or the woman’s lack of interest in being screened via mammographic interpretation
  • wearable technology that accurately detects breast cancer through tracking metabolic changes as a woman navigates through her normal daily routine
  • Dense tissue affects over 50% of the female population leading to an earlier onset of cancer and over 70% of biopsy’s occurring on non-cancerous tissue

17:50 End of day 2: Poster viewing and networking drinks reception

last published: 15/Feb/18 14:19 GMT

 

DOWNLOAD BROCHURE

 

Sign Up for Event Updates

World Precision Medicine Congress

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com